<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784640</url>
  </required_header>
  <id_info>
    <org_study_id>L-05</org_study_id>
    <secondary_id>NCI-2013-00410</secondary_id>
    <secondary_id>12-001489</secondary_id>
    <nct_id>NCT01784640</nct_id>
  </id_info>
  <brief_title>Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously-Treated Patients With Metastatic Non-Squamous, Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and the best dose of Hsp90 inhibitor AUY922 when
      given together with pemetrexed disodium in treating patients with previously treated stage IV
      non-small cell lung cancer. Hsp90 inhibitor AUY922 may stop the growth of tumor cells by
      blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
      pemetrexed disodium, work in different ways to stop the growth of tumor cell, either by
      killing the cells or stopping them from dividing. Giving Hsp90 inhibitor AUY922 together with
      pemetrexed disodium may kill more tumor cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the safety and tolerability of escalating doses of AUY922 (Hsp90 inhibitor
      AUY922) when given with pemetrexed (pemetrexed disodium) 500 mg/m^2 in participants with
      previously-treated stage IV non-squamous, non-small cell lung cancer (NSCLC).

      SECONDARY OBJECTIVES:

      I. Determine the objective tumor response rate as defined by Response Evaluation Criteria in
      Solid Tumors (RECIST) 1.1 criteria in participants with previously treated non-squamous NSCLC
      treated with pemetrexed and AUY922.

      II. Evaluate the pharmacokinetic profile of pemetrexed and AUY922. III. Evaluate toxicity,
      including visual toxicity, in participants treated with AUY922 and pemetrexed.

      IV. Analyze tumor-tissue biomarkers for potential correlation with response.

      OUTLINE: This is a dose-escalation study of Hsp90 inhibitor AUY922.

      Patients receive Hsp90 inhibitor AUY922 intravenously (IV) over 60 minutes weekly and
      pemetrexed disodium IV over 15 minutes every 3 weeks. Courses repeat every 21 days for 6
      months in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2014</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) as assessed by National Cancer Institute (NCI) CTCAE version 4.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Safety will be assessed through tabulation, grading and attribution of serious adverse events (SAEs) and AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate according to RECIST version 1.1</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>The proportion of ever achieving a clinical response will be estimated and constructed with an exact one-sided 90% confidence interval to identify the likely range for the underlying tumor response rate. Clinical response will be correlated with biomarkers using a variety of analytic techniques.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Squamous Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Hsp90 inhibitor AUY922 IV over 60 minutes weekly and pemetrexed disodium IV over 15 minutes every 3 weeks. Courses repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hsp90 inhibitor AUY922</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)</arm_group_label>
    <other_name>AUY922</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)</arm_group_label>
    <other_name>ALIMTA</other_name>
    <other_name>LY231514</other_name>
    <other_name>MTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information (PHI) in
             accordance with national and local subject privacy regulations

          -  Histologically- or cytologically-confirmed stage IV non-squamous, NSCLC who have
             progressed after at least one prior line of treatment; in the expansion phase,
             participants are only eligible if their molecular category has not been fully enrolled
             (10 participants with epidermal growth factor receptor (EGFR) mutations, 5
             participants with anaplastic lymphoma receptor tyrosine kinase (ALK) gene
             rearrangement, 5 participants with wild type v-Ki-ras2 Kirsten rat sarcoma viral
             oncogene homolog (KRAS), EGFR and ALK)

          -  At least one measurable lesion as defined by modified RECIST version 1.1; previously
             irradiated lesions are not measurable unless the lesion is new or has demonstrated
             clear progression after radiation

          -  Last chemotherapy or treatment with another systemic anti-cancer agent must have
             stopped &gt;= 4 weeks prior to enrollment (or &gt;= 5 half-lives for oral tyrosine-kinase
             inhibitors or 2 weeks for palliative radiotherapy); participants must have recovered
             (Common Terminology Criteria for Adverse Events [CTCAE] =&lt; 1 or baseline) from acute
             toxicities of any previous therapy (with the exception of alopecia)

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Expected survival time of &gt;= 3 months in the opinion of the investigator

          -  Absolute neutrophil count (ANC) &gt;=1.5 x 10^9/L

          -  Hemoglobin (Hgb) &gt;= 9 g/dl

          -  Platelets (plt) &gt;= 100 x 10^9/L

          -  Potassium within normal limits

          -  Total calcium (corrected for serum albumin) within normal limits or corrected with
             supplements

          -  Magnesium within lower limits or corrected with supplements

          -  Phosphorus within lower limits or corrected with supplements

          -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and
             alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =&lt; 1.5 x
             upper limit of normal (ULN)

          -  AST/SGOT and ALT/SGPT =&lt; 2.5 x upper limit of normal (ULN) if liver metastases are
             present

          -  Serum bilirubin =&lt; 1.5 x ULN

          -  Serum creatinine =&lt; 1.5 x ULN or 24-hour clearance &gt;= 50 ml/min

          -  Negative serum or urine pregnancy test; the serum pregnancy test must be obtained
             prior to the first administration of AUY922 (=&lt; 14 days prior to dosing) in all
             pre-menopausal women and women &lt; 2 years after the onset of menopause

          -  Ability to provide a formalin-fixed, paraffin-embedded (FFPE) tumor tissue sample
             containing representative tumor tissue from a previously obtained biopsy/resection
             that meets specific tissue sample requirements at screening

        Exclusion Criteria:

          -  Unresolved diarrhea &gt;= CTCAE (v4.0) grade 1

          -  Pregnant or lactating women

          -  Fertile women of childbearing potential (WCBP) not using (or refusing to use) adequate
             methods of contraception as agreed on between her and the consenting investigator;
             male participants not using (or refusing to use) a condom during intercourse

          -  History of another primary cancer within 3 years prior to enrollment with the
             exception of curatively treated skin cancer (other than melanoma) or curatively
             treated cervical carcinoma in-situ

          -  History of central nervous system (CNS) metastasis; Note: participants without
             clinical signs and symptoms of CNS involvement are not required to have magnetic
             resonance imaging (MRI) of the brain; (exception: participants with treated brain
             metastases who are asymptomatic, not currently on steroid therapy, and clinically
             stable for &gt;= 2 weeks will be eligible for protocol participation)

          -  Prior treatment with pemetrexed

          -  Prior anti-neoplastic treatment with any heat shock protein 90 (HSP90) or histone
             deacetylase (HDAC) inhibitor compound

          -  Participants who have undergone any major surgery =&lt; 2 weeks prior to starting study
             drug or who have not recovered from side effects of such therapy

          -  Last chemotherapy or treatment with another systemic anti-cancer agent must have
             stopped &gt;= 4 weeks prior to enrollment (or &gt;= 5 half-lives for oral tyrosine-kinase
             inhibitors); participants with EGFR mutations and ALK gene rearrangement who have not
             received a tyrosine kinase inhibitor targeting their molecular abnormality (e.g.,
             erlotinib or crizotinib respectively); participants must have recovered (CTCAE =&lt; 1)
             from acute toxicities of any previous therapy (with the exception of alopecia)

          -  Participants who have concurrent or uncontrolled illness that the investigator feels
             will impede study participation including, but not limited to:

               -  Acute or chronic liver disease

               -  Acute or chronic renal disease

               -  Active or ongoing infection

               -  Psychiatric illness/social situations that would limit compliance with study
                  requirements

          -  Participants with known disorders due to a deficiency in bilirubin glucuronidation
             (e.g. Gilbert's syndrome)

          -  Intolerance of Vitamin B12, folic acid or dexamethasone

          -  Participants with following cardiac criteria:

               -  History of long QT syndrome

               -  QTcF &gt;= 450 ms during screening electrocardiogram (ECG)

               -  History of clinically manifest ischemic heart disease including myocardial
                  infarction, stable or unstable angina pectoris, coronary arteriography or cardiac
                  stress testing/imaging with findings consistent with infarction or clinically
                  significant coronary occlusion â‰¤ 6 months prior to study start

               -  History of heart failure or left ventricular (LV) dysfunction (LV ejection
                  fraction [EF] =&lt; 45%) by multi gated acquisition scan (MUGA) or echocardiogram
                  (ECHO)

               -  Clinically significant ECG abnormalities including one or more of the following:
                  left bundle branch block (LBBB), right bundle branch block (RBBB) with left
                  anterior hemiblock (LAHB); ST segment elevations or depressions &gt; 1mm, or 2nd
                  (Mobitz II) or 3rd degree atrioventricular block (AV) block

               -  History and presence of atrial fibrillation, atrial flutter or ventricular
                  arrhythmias including ventricular tachycardia or Torsades de pointes

               -  Other clinically significant heart disease (e.g. congestive heart failure,
                  uncontrolled hypertension, history of labile hypertension, or history of poor
                  compliance with a hypertensive regimen)

               -  Clinically significant resting bradycardia (&lt; 50 beats per minute)

               -  Participants who are currently receiving treatment with any medication which has
                  a relative risk or prolonging the QTcF interval or inducing Torsades de pointes
                  (as listed in protocol) and cannot be switched or discontinued to an alternative
                  drug prior to commencing AUY922 dosing

               -  Participants who are on a cardiac pacemaker

          -  Participants unwilling or unable to comply with the protocol

          -  Participants known to be human immunodeficiency virus (HIV) positive; testing is not
             required in the absence of clinical signs and symptoms suggesting HIV infection

          -  Any systemic anti-cancer treatment out of allowed timelines

          -  Concurrent cytotoxic or immunosuppressive therapy for non-malignant disease (e.g., for
             rheumatoid arthritis or lupus)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Garon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2013</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

